Review of recent advances in managing periocular skin malignancies.

Autor:	Trotier DC; University of Wisconsin School of Medicine & Public Health, Madison, WI, United States.; Department of Medicine, Division of Hematology, Medical Oncology, and Palliative Care, University of Wisconsin-Madison, Madison, WI, United States., Huang L; University of Wisconsin School of Medicine & Public Health, Madison, WI, United States., van Landingham SW; University of Wisconsin School of Medicine & Public Health, Madison, WI, United States.; Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, United States., Burr AR; University of Wisconsin School of Medicine & Public Health, Madison, WI, United States.; Department of Human Oncology, University of Wisconsin-Madison, Madison, WI, United States.; University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, United States., Ma VT; University of Wisconsin School of Medicine & Public Health, Madison, WI, United States.; Department of Medicine, Division of Hematology, Medical Oncology, and Palliative Care, University of Wisconsin-Madison, Madison, WI, United States.; University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, United States.; Department of Dermatology, University of Wisconsin-Madison, Madison, WI, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2024 Mar 04; Vol. 14, pp. 1275930. Date of Electronic Publication: 2024 Mar 04 (Print Publication: 2024).
DOI:	10.3389/fonc.2024.1275930
Abstrakt:	Management of cutaneous malignancies can be particularly challenging when they are located in the periocular region. The standard of care for localized disease is complete surgical excision, but this may not be possible without significant disruption to visual structures and facial appearance. Definitive radiation may be an option for some patients who cannot or do not wish to undergo surgery. Advances in systemic treatment options for locally advanced and metastatic skin cancers in the past 10 years have prompted investigation into neoadjuvant treatment of periocular cancers. The use of chemotherapy, immune checkpoint inhibitors, and targeted therapies have all been reported with varying degrees of success. For many patients, targeted therapies or immune checkpoint inhibitors should be considered depending on the cancer type, symptoms, and goals with the input of a multidisciplinary cancer care team. In this article, we systematically review the latest updates in surgical, radiotherapeutic, and medical management of periocular malignancies. Competing Interests: VM serves as a consulting or advisory role for Immunocore, Regeneron Pharmaceuticals, Teiko.bio, Incyte, Replimune, Partner Therapeutics, and Bristol Myers Squibb. SV is an investigator on clinical trials sponsored by Immunovant and Sling Therapeutics that are unrelated to the contents of this manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest. (Copyright © 2024 Trotier, Huang, van Landingham, Burr and Ma.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu